synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-01 and is reviewed periodically as new material appears.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
== Structure-activity relationships == There is a rather large homology in structure between arenobufagin and cardiac glycosides. Cardiac glycosides are natural compounds found in plants which cause inactivation of the sodium potassium pump like arenobufagin. The specific steroidic structure binds to the pump in a way it inhibits the process of pumping potassium into the cell and sodium out of the cell. The exact way of binding to the Na-K-Pump is not yet documented.
=== Transdermal patch === Transdermal patches can be a very precise time released method of delivering a drug. Cutting a patch in half might affect the dose delivered. The release of the active component from a transdermal delivery system (patch) may be controlled by diffusion through the adhesive which covers the whole patch, by diffusion through a membrane which may only have adhesive on the patch rim or drug release may be controlled by release from a polymer matrix. Cutting a patch might cause rapid dehydration of the base of the medicine and affect the rate of diffusion.
=== Infection === Infection will complicate healing of surgical wounds and is commonly observed. Most infections are present within the first 30 days after surgery. Surgical wounds can become infected by bacteria, regardless if the bacteria is already present on the patient's skin or if the bacteria is spread to the patient due to contact with infected individuals. Wound infections can be superficial (skin only), deep (muscle and tissue), or spread to the organ or space where the surgery occurred. Recent studies have established that infection after surgery can occur after several years post surgery, and these infection rates are not recorded due to loss in patient follow up, hard to access record of previous surgery, visiting a new surgeon, lack of requirement from national registries etc.
Sources: en.wikipedia.org
Under its terms the Basuto would be allowed to keep their guns, provided they officially register them and pay an annual fee of one pound per weapon. The Cape pledged to provide an amnesty for the rebels and allow for Quthing to remain a part of Basutoland. The Basuto agreed to pay a collective fine of 5,000 cattle and compensate Basuto loyalists and white traders. The Award marked the end of the conflict. The Cape's casualties during the war totaled 94 killed and 112 wounded.
selfish genetic element Also selfish DNA or parasitic DNA. Any genetic material (e.g. a gene or any other DNA sequence) which can enhance its own replication and/or transmission into subsequent generations at the expense of other genes in the genome, even if doing so has no positive effect or even a net negative effect on the fitness of the genome as a whole. Selfish elements usually work by producing self-acting gene products which repeatedly copy and paste their own coding sequences into other parts of the genome, independently of normal DNA replication (as with transposable elements); by facilitating the uneven swapping of chromosome segments during genetic recombination events (as with unequal crossing over); or by disrupting the normally equal redistribution of replicated material during mitosis or meiosis such that the probability that the selfish element is present in a given daughter cell is greater than the normal 50 percent (as with gene drives).
DWNT synthesis on the gram-scale by the CCVD technique was first proposed in 2003 from the selective reduction of oxide solutions in methane and hydrogen. The telescopic motion ability of inner shells, allowing them to act as low-friction, low-wear nanobearings and nanosprings, may make them a desirable material in nanoelectromechanical systems (NEMS) . The retraction force that occurs to telescopic motion is caused by the Lennard-Jones interaction between shells, and its value is about 1.5 nN.
=== 26 July === Russian forces captured the village of Lozuvatske in Donetsk Oblast, 24 kilometers east of Pokrovsk. The FSB announced the arrest of a suspect in the 24 July car bombing in Moscow who had been extradited from Turkey, claiming that he was a Russian national who carried out the attack on behalf of Ukrainian intelligence. Explosions were reported at Saky airfield in Crimea, and a drone attack on Sevastopol was reported. Russian authorities claimed that 21 drones were shot down over Bryansk Oblast.
Sources: en.wikipedia.org
=== Features === The project led by MSRDC will observe international road design and safety standards, with an intelligent highway management system for traffic surveillance. The expressway is designed for a top speed of 150 km/h on plain terrain and 120 km/h on hilly terrain, even though the legal speed limit remains at 120 km/h for cars and 80 km/h for trucks, enforceable by CCTV cameras, making it the fastest road network in the country, which will cut down the travel time between the two cities to eight hours from the present 16-hour. The Super Communication Expressway will considerably contribute to the 6% to the national trunk and freight infrastructure. Nearly 36% of the state population will observe the Samruddhi Corridor as a substantial growth driver, putting a direct positive impact on their livelihood. The MSRDC has been authorized as a nodal agency, the New Town Development Authority (NTDA), for developing 19 new townships along the route, which will include state-of-the-art healthcare facilities, skill development centers, IT parks, and educational institutions. The expressway will pass through 3 wildlife sanctuaries, including a 29.6 km passage through the Katepurna Wildlife Sanctuary in Akola, 29.15 km through the Karanja-Sohol Black Buck Sanctuary in Washim, and 44.975 km through the Tansa Wildlife Sanctuary in Thane. The Mumbai–Nagpur Expressway has been envisioned to ensure zero fatalities, and will have CCTVs and free telephone booths at every 5 km interval in case of an emergency.
Critics gave Darbar mixed reviews. On the review aggregator website Rotten Tomatoes, 50% of 8 critics' reviews are positive, with an average rating of 6.2/10. Sreedhar Pillai, writing for Firstpost gave Darbar a rating of two-and-tree-quarter stars out of five and stated "The first half of Darbar is enjoyable mainly due to Rajinikanth's style and swagger". Saibal Chatterjee of NDTV gave the film two-and-a-half stars out of five and wrote "Darbar is targeted fair and square at Rajinikanth fans, but it does nothing to give masala cinema a fresh shot of energy". Writing for The Times of India, M Suganth gave three stars out of five and stated "Darbar is an engaging commercial cocktail of action and drama". Shubhra Gupta, editor-in-chief of The Indian Express, gave two-and-a-half stars out of five and stated "Darbar remains a Rajinikanth film which bows at each step to the continuing myth of the one and only Thalaivar". S Srivatsan from The Hindu stated "Despite A.R. Murugadoss offering very little substance for him to work with, the superstar just about manages to carry this film on his aging shoulders". Sify gave two-and-a-half stars out of five and stated, "Darbar is an average cop action entertainer packed to satisfy the appetite of the die-hard fans of Thalaivar". Karthik Kumar of Hindustan Times wrote "AR Murugadoss plays on Rajinikanth's strength and swag, but everything else in this film gets a lackadaisical treatment". Baradwaj Rangan wrote for Film Companion, "The film falls in a no-man's land, where the drama and the action is neither powerful nor punchy enough".
== Modulators == Dihexa is an orally active, centrally penetrant small-molecule compound that directly binds to HGF and potentiates its ability to activate its receptor, c-Met. It is a strong inducer of neurogenesis and is being studied for the potential treatment of Alzheimer's disease and Parkinson's disease.
=== Hormone claim retracted === Although the original cytokine function of PBEF has not been confirmed to date, others have since reported or suggested a cytokine-like function for this protein. In particular, Nampt/PBEF was recently re-identified as a "new visceral fat-derived hormone" named visfatin. It is reported that visfatin is enriched in the visceral fat of both humans and mice and that its plasma levels increase during the development of obesity. Noteworthy is that visfatin is reported to exert insulin-mimetic effects in cultured cells and to lower plasma glucose levels in mice by binding to and activating the insulin receptor. However, the physiological relevance of visfatin is still in question because its plasma concentration is 40 to 100-fold lower than that of insulin despite having similar receptor-binding affinity. In addition, the ability of visfatin to bind and activate the insulin-receptor has yet to be confirmed by other groups. On 26 October 2007, A. Fukuhara (first author), I.Shimomura (senior author) and the other co-authors of the paper, who first described Visfatin as a visceral-fat derived hormone that acts by binding and activating the insulin receptor, retracted the entire paper at the suggestion of the editor of the journal 'Science' and recommendation of the Faculty Council of Osaka University Medical School after a report of the Committee for Research Integrity.
==== Shoulder replacement ==== For people who have shoulder osteoarthritis and do not respond to medications, surgical options include a shoulder hemiarthroplasty (replacing a part of the joint) and a total shoulder arthroplasty (replacing the joint). Demand for this treatment is expected to increase by 750% by the year 2030. There are different options for shoulder replacement surgeries, however there is a lack of evidence in the form of high-quality randomized controlled trials to determine which type of shoulder replacement surgery is most effective in different situations, what are the risks involved with different approaches, or how the procedure compares to other treatment options. There is some low-quality evidence that indicates that when comparing total shoulder arthroplasty over hemiarthroplasty, no large clinical benefit was detected in the short term. It is not clear if the risk of harm differs between total shoulder arthroplasty and a hemiarthroplasty approach.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.